Kura Oncology, Inc. KURA
We are a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Since our founding in 2014, we have transformed from a research and development company to a fully-integrated commercial-stage organization with a diversified pipeline of product candidates. Our pipeline consists of small molecules designed to target cancer signaling pathways and address significant unmet needs in oncology and hematology.
2025 was a pivotal year for our company. On November 13, 2025, the FDA approved our new drug application, or NDA, for ziftomenib, which is being marketed in the United States under the trade name KOMZIFTITM, for the treatment of adults with relapsed or refractory acute myeloid leukemia, or AML, with a susceptible nucleophosmin 1, or NPM1, mutation who have no satisfactory alternative treatment options. KOMZIFTI is the first and only menin inhibitor approved by the FDA for once-daily oral administration.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $67.5M | $53.9M | $0 | — | — | — | — | — | — | — |
| R&D | $251.1M | $170.0M | $115.2M | $92.8M | $84.7M | $60.4M | $47.8M | $46.8M | $26.4M | — |
| SG&A | $120.0M | $77.1M | $50.6M | $47.1M | $46.5M | $31.5M | $19.7M | $16.1M | $9.7M | — |
| Total operating expenses | $371.1M | $247.1M | $165.8M | $139.9M | $131.3M | $91.9M | $67.5M | $62.9M | $36.1M | $28.4M |
| Operating income | -$303.6M | -$193.2M | -$165.8M | -$139.9M | — | — | — | — | — | — |
| Interest expense | $1.5M | $1.6M | $1.5M | $229.0K | $414.0K | $578.0K | $580.0K | $970.0K | $888.0K | $577.0K |
| Pre-tax income | -$278.4M | -$172.0M | -$152.6M | -$135.8M | -$130.5M | -$89.6M | -$63.1M | -$60.4M | -$35.4M | -$27.6M |
| Income tax | $297.0K | $2.0M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$278.7M | -$174.0M | -$152.6M | -$135.8M | -$130.5M | -$89.6M | -$63.1M | -$60.4M | -$35.4M | -$27.6M |
| EPS, basic | -3.18 | -2.02 | -2.08 | -2.03 | -1.97 | -1.69 | — | — | — | — |
| EPS, diluted | -3.18 | -2.02 | -2.08 | -2.03 | -1.97 | -1.69 | -1.51 | -1.72 | -1.52 | -1.47 |
| Shares, diluted (wtd. avg.) | 87.7M | 86.2M | 73.2M | 67.0M | 66.4M | 53.1M | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $149.1M | $224.5M | $37.3M | $51.8M | $90.7M | $325.5M | $26.1M | $16.1M | $11.4M | $9.7M |
| Short-term investments | $518.1M | $502.9M | $386.6M | $386.2M | $427.3M | $307.8M | $210.8M | $162.9M | $81.7M | — |
| Receivables | $8.8M | $2.1M | — | — | — | — | — | — | — | — |
| Inventory | $413.0K | $0 | — | — | — | — | — | — | — | — |
| Total current assets | $708.7M | $744.8M | $432.5M | $446.4M | $522.3M | $637.3M | $239.6M | $181.2M | $94.6M | $68.8M |
| Property, plant and equipment | $7.9M | $1.7M | $1.9M | $2.5M | $2.7M | $2.0M | $44.0K | — | $10.0K | $40.0K |
| Total assets | $738.4M | $760.2M | $448.9M | $456.3M | $534.1M | $647.2M | $242.0M | $182.4M | $95.9M | $69.8M |
| Accounts payable | $5.0M | $1.5M | $2.3M | $1.5M | $3.2M | $2.8M | $3.5M | $3.9M | $1.2M | $638.0K |
| Short-term debt | $0 | $2.6M | — | — | — | $3.0M | $250.0K | — | $1.5M | — |
| Total current liabilities | $117.0M | $78.7M | $35.3M | $24.1M | $22.5M | $26.0M | $15.6M | $13.6M | $10.0M | $5.5M |
| Long-term debt | $9.7M | $6.9M | $9.3M | $9.2M | — | $4.2M | $7.2M | $7.5M | $5.6M | $7.3M |
| Total liabilities | $564.2M | $346.5M | $51.7M | $36.0M | $27.4M | $36.3M | $23.2M | $21.4M | $16.0M | $12.9M |
| Retained earnings | -$1.17B | -$895.4M | -$721.4M | -$568.8M | -$433.0M | -$302.5M | -$212.9M | -$149.7M | -$89.3M | -$53.9M |
| Total equity | $174.1M | $413.6M | $397.3M | $420.3M | $506.6M | $610.9M | $218.8M | $161.0M | $79.9M | $56.9M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$64.1M | $134.3M | -$124.8M | -$110.1M | -$104.6M | -$69.8M | -$54.8M | -$48.7M | -$28.4M | -$25.3M |
| Depreciation and amortisation | $1.0M | $848.0K | $849.0K | $759.0K | $558.0K | $194.0K | $0 | $10.0K | $30.0K | $31.0K |
| Stock-based compensation | $37.1M | $33.9M | $28.1M | $26.3M | $23.6M | $12.8M | $9.4M | $8.7M | $4.5M | $2.1M |
| Capital expenditure | $6.6M | $472.0K | $168.0K | $626.0K | $1.1M | $2.2M | — | — | — | — |
| Investing cash flow | -$13.1M | -$101.6M | $15.6M | $32.6M | -$126.8M | -$99.9M | -$46.3M | -$79.3M | -$23.4M | $12.2M |
| Financing cash flow | $1.8M | $154.4M | $94.8M | $38.6M | -$3.4M | $469.3M | $111.1M | $132.6M | $53.6M | $7.5M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-151335.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | $0 | $53.9M | $67.5M |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | -$27.6M | -$35.4M | -$60.4M | -$63.1M | -$89.6M | -$130.5M | -$135.8M | -$152.6M | -$174.0M | -$278.7M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Officer or director change Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Results announced Item 2.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Other event Item 8.01
- Results announced Item 2.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |